Abametapir and Rifabutin: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jun 30, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Abametapir
No brand names on recordRifabutin
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Abametapir is a lotion used to treat head lice, and rifabutin is an antibiotic often used against certain serious infections. Even though abametapir is a scalp treatment, a little bit gets into your body and can temporarily block one of your liver's cleanup enzymes (called CYP3A4). Rifabutin is broken down by that same enzyme, so it may build up higher than usual for a while, which could raise the chance of side effects.
The good news is this is easy to plan around. Please don't stop either medicine on your own. Just let your pharmacist or doctor know you use both so they can guide the timing safely.
Mechanism: Abametapir inhibits CYP3A4. Rifabutin is a CYP3A4 substrate, so co-administration is expected to reduce its metabolism and increase systemic exposure (AUC/Cmax), potentially amplifying rifabutin-related toxicity (e.g., uveitis, neutropenia, GI effects).
- Direction: Increased rifabutin exposure.
- Onset: Rapid; enzyme inhibition persists, so effect can last after a single topical application.
- Evidence: Theoretical, based on abametapir's known CYP3A4 inhibition.
- Management: Avoid CYP3A4 substrates for 2 weeks following abametapir application. If concurrent therapy is unavoidable, avoid abametapir. Consider closer monitoring for rifabutin toxicity if exposure occurs.
What happens
Increased exposure of CYP3A4 substrate
Interaction Deep Dive
For a period of 2 weeks following the application of abametapir, do not use CYP3A4 substrates. Should avoidance of these substrates not be practical, then abametapir itself should be avoided 1.
Why it happens (mechanism)
Inhibition of CYP3A4-mediated metabolism by abametapir
How to manage this interaction
Your care team can manage this with simple timing and awareness.
- Keep taking your prescribed medicines and do not stop either one on your own.
- Tell your pharmacist or prescriber that you use both, since guidance is to avoid CYP3A4-metabolized drugs like rifabutin for 2 weeks after applying abametapir.
- If both are truly needed, the team may choose to hold or avoid the abametapir instead, or watch you more closely for rifabutin side effects.
- Report any new eye discomfort, unusual bruising, fever, or stomach upset.
Management is individual — confirm any change with your pharmacist or prescriber.
Common questions
Can I take Abametapir and Rifabutin together?
Abametapir can raise rifabutin levels by blocking the enzyme that clears it, so avoid rifabutin for two weeks after applying abametapir. Ask your pharmacist or doctor to help you plan the timing before using both. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Abametapir and Rifabutin interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "rapid". Effects can appear quickly, often within about 24 hours of combining the drugs.
How is the Abametapir and Rifabutin interaction managed?
Your care team can manage this with simple timing and awareness. Keep taking your prescribed medicines and do not stop either one on your own. Tell your pharmacist or prescriber that you use both, since guidance is to avoid CYP3A4-metabolized drugs like rifabutin for 2 weeks after applying abametapir. If both are truly needed, the team may choose to hold or avoid the abametapir instead, or watch y… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Abametapir or Rifabutin need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: XEGLYZE(TM) topical lotion, abametapir topical lotion. Dr Reddy’s Laboratories Inc (per FDA), Princeton, NJ, 2020. DailyMed
Keep reading about Abametapir
Keep reading about Rifabutin
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist